
pm et
summari global medic product servic compani provid hospit suppli renal
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
see sale inclus acquir
clari inject rise
initi anticip growth howev
manag highlight sale
large-volum iv solut spike first
five month lead inventori
destock across custom issu
expect remedi
seem unlik result
made signific manag chang
look three largest
segment revenu see
organ growth renal care medic
deliveri pharmaceut
set aggress goal achiev
oper margin end
prudent cost cut product
portfolio chang achiev oper
margin vs
expect basi point bp
oper margin expans
mean achiev bp
expans
find right acquisit
rang higher margin
product cost synergi perhap could
achiev lofti target
although view portfolio restructur
posit think share trade
forward earn price near
intrins valu forecast grow sale
compound annual growth rate
expect oper margin
reach although view
sale goal achiev
skeptic margin expans goal
expect seek strateg acquisit
help achiev margin expans goal
think secular long-term trend posit
compani maintain
above-p valuat must demonstr
abil innov futur pipelin
risk recommend target price
includ failur achiev meaning oper
margin expans dearth invest
headwind sale cyclophosphamid
gener competit failur develop new
product drive futur sale growth
target price base
ep estim
price-to-earnings rang
risk assess reflect oper highli
competit busi character rapid
technolog chang new market entrant
addit busi entail regulatori
reimburs risk well liabil risk
malfunct product off-set view
health care product larg immun econom
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid broad portfolio essenti healthcar
product includ acut chronic dialysi therapi steril intraven iv solut infus
system devic parenter nutrit therapi inhal anesthet gener inject
pharmaceut surgic hemostat sealant product baxter ad capabl
product essenti gener inject medicin acquisit clari inject limit
clari compani global footprint critic natur product servic play key role
expand access healthcar emerg develop countri product use
hospit kidney dialysi center nurs home rehabilit center doctor offic patient
home physician supervis decemb baxter manufactur product
countri sold countri
chang commerci structur report financi perform base follow
geograph segment america north south america emea europ middl east africa
apac asia-pacif revenu gener outsid unit state geograph
expans remain compon compani strategi gener approxim
revenu outsid unit state america made total revenu emea
apac
global busi unit renal care acut therapi medic deliveri
pharmaceut nutrit advanc surgeri largest unit renal care billion
revenu medic deliveri billion pharmaceut billion combin
renal includ sale periton dialysi hemodialysi machin well addit
dialysi therapi servic medic deliveri includ sale iv therapi infus pump
administr set drug reconstitut devic unit includ sale
compani premix oncolog drug platform inhal anesthesia critic care product
corpor strategi focus sever key object success execut long-term
strategi achiev sustain growth deliv enhanc stockhold valu baxter diversifi
broad portfolio medic product treat life-threaten acut chronic condit global
presenc core compon compani strategi achiev object compani
focus three strateg factor part pursuit industri lead perform optim
core portfolio global oper excel focus streamlin cost structur enhanc
oper effici follow disciplin balanc approach capit alloc
expect seek strateg acquisit help achiev goal acquir clari
inject limit clari produc gener inject medicin anesthesia analges
million
competit landscap although lead posit key market must still contend
signific competit pressur market baxter face substanti competit
segment intern domest healthcar pharmaceut compani provid
size competitor often differ across busi competit primarili focus
cost-effect price servic product perform technolog innov
increas consolid compani custom base competitor continu result
price market pressur
major develop juli spun-off biopharmaceut busi separ
trade public compani name baxalta oper result baxalta reflect
financi trend baxter global net sale total billion increas
report constant currenc basi sale total billion increas
compar report constant currenc basi sale unit state total
billion increas compar earn per share vs
flow oper increas year-over-year billion net debt total
capit ratio histor low march
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
product fda grant regulatori discret temporari special
import certain product facil ireland australia canada
mexico still expect advers revenu impact /jeffrey loo
rais target peer
forward ep estim encourag bax
portfolio chang drive growth margin ep vs
ahead estim rais ep estim
estim includ pend acquisit clari
expect close end juli sale rose sale
oversea sale hospit product sale rose renal sale flat
analyst research note compani news
inc lower target
ep estim multipl low-end
rang sinc juli baxalta divestitur ep
vs higher estim rais ep
lower ep earn
call manag highlight sale large-volum iv solut
spike first month year lead inventori destock across
custom result lower sale growth guidanc
previou guidanc sale increas organ
billion growth constant currenc cc america
growth cc emea declin cc apac expect
improv medic deliveri clinic nutrit segment
segment experienc low-single-digit cc sale declin /kevin
inc rais target
above-p ep estim
multipl near middl bax rang sinc juli baxalta
divestitur ep vs higher
estim rais ep
ep sale increas organ billion
growth constant currenc cc america growth cc
emea growth cc apac weaker segment quarter
medic deliveri saw cc sale declin year-over-year clinic
nutrit saw cc sale declin expect turn segment
around posit growth see sale grow cc
organ basi /kevin huang cfa
inc rais target
above-p next-twelve-month ep estim
multipl near middl bax rang sinc juli
baxalta divestitur ep vs
higher estim rais ep
ep sale increas billion
growth us growth intern look bax
largest segment revenu see organ growth
renal care medic deliveri pharmaceut
adjust oper margin declin basi point despit
underli oper expans due loss transit servic incom
foreign exchang linger hurrican impact expect oper margin
improv come quarter rais ep guidanc prior rang
higher-than-expect sale year
inc rais target above-p
ep estim industri averag
margin expans set ep ep vs
ahead estim sale rose hospit product sale
renal sale puerto rico facil back product
compani expect normal product level come week still
see advers sale impact expect continu
restructur product portfolio acquisit divestitur
inc keep target above-p
forward ep estim faster margin expans
ep vs ahead estim lift ep
estim sale rose hospit product renal
manufactur facil puerto rico remain limit
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
